Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine

 

• Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
• 15 out of the 16 patients had reduction of their tumors (target lesions)
• The complete one-year dataset will be presented at the ESMO congress this week and discussed at a webinar with key opinion leader Professor Georgina V. Long on September 18, 2024

https://www.globenewswire.com/news-release/2024/09/09/2942789/0/en/Evaxion-reports-69-Overall-Response-Rate-in-its-phase-2-trial-on-lead-cancer-vaccine-candidate-EVX-01.html